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David Camilleri 
With the 31st of December 1992 being so close at hand, the 
Administrative Institutions of the E.C. are hard at work in drawing-up, 
adopting, and enforcing Community law so as to fuIfiII their commitment 
towards the formation of a Single European Market by the deadline 
indicated above. 
The principal aim and goal of the single European Market is the birth of 
a European area through which goods, persons, capital, and services can 
move freely without having to overcome the physical, technical and 
fiscal barriers to trade, which currently exist between the different 
European nations. 
Like all other sectors, the Pharmaceutical environment will be greatly 
effected by the changes resulting from a united Europe. 
In view of Malta's application to join the Community, the Maltese 
Pharmaceutical sector should, and has the obligation to identify these 
changes and take the appropriate measure to bring the Maltese 
Pharmaceutical environment in liason with that of the E.C. 
In this respect, two main areas of concern are identified: 
a) The free movement of pnarmacists, and 
b) The free movement of pharmaceuticals and medical/surgical 
products 
A) The free movement of pharmacists 
The social Charter of the E.C. is aimed at guarante~ing the free 
movement, and equal treatment of workers throughout the Community. It 
encompasses the basic rights for workers so as to ensure that workers can 
work, look for work, reside, etc... in anyone of the 12 M~mber States 
without prejudice. 
In respect of professional workers, the Community has taken measures to 
ensure that Diplomas & Professional Qualifications obtained in any 
member state is recognised in all the other member states. 
For pharmacy, 3 main Directives were adopted so as to: 
i) facilitate the free movement of pharmacists (Dir. 85/432/EEO 
ii) have a mutual recognition of Diplomas (Dir. 85/433/EEC) 
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iii) set up an Advisory Committee on pharmaceutical training 
requirements (Dir. 85/434/EEO 
The' adoption of these Directives has enabled the free movement of 
pharmacists throughout the Community by eliminating the 'visible' 
barriers which limited the free movement of pharmacists within the 
E.C 
Apart from these barriers, there also exist 'invisible' barriers, such as the 
local language, environment, lifestyle, etc... These barriers are being 
tackled through the implementation of various programmes (e.g. Lingua, 
Erasmus, Cornett) aimed at promoting the 'European' concept. 
When looking at Malta, one notices the existence of several barriers 
limiting the free movement of pharmacists. These barriers include: 
Pharmacy Diploma recognition. Maltese Pharmacy Diploma is 
not recognised in all of E:C's member states, thus limiting the 
movement of Maltese Pharmacists. 
- Pharmacy course content. This is still not up to the minimum 
Diploma requirements as described by E.C Directives. This 
problem has been identified and various steps are being taken in 
order to bring current course content in line with that stipulated by 
the E.C 
Immigration barriers, including work permits, residence permits, 
etc ... 
Language barrier.Very few foreign Pharmacists know the Maltese 
language, thus limiting the possibility of their working in the 
Maltese community. 
Wages, which are not as attractive as those in other E.C member 
states. 
B) The free movement of Pharmaceuticals 
In this sector the main barriers are the so called Technical barriers of 
which there are three: 
i) Differences in national standards 
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i i) Differences in national regulations 
i i i) Testing and certification procedures 
The Community is working to remove these barriers through the 
harmonisation of laws and regulations governing pharmaceuticals and 
the standardisation of requirements for pharmaceuticals. These efforts 
may be grouped in two: 
1) Efforts to harmonise required standards 
Here, one can mention the elaboration of the European Pharmacopeia, 
European/Community patent, defining the legal status of the various 
drug classes, the setting up of a Common Market Authorisation procedure 
(based on two systems; the centralJsed and the decentralised systems). 
2) Efforts to harmonise testing and certification 
Efforts in this field are mainly aimed at encouraging mutual recognition 
of existing national testing and certification methods, and the issuing of 
guidelines for GMP, GLC, GCP etc ... 
The establishment of the European Organisation for Testing and 
Certification, is aimed at realizing this goal by promoting and 
implementing agreed crHeria and procedures from' the technical 
capabilities, operational performance and maintenance of competence of 
operators. 
It is important to realise that the Community makes these efforts in 
liason with similC1r initiatives taken by international Organisations (e.g. 
ISO, lEC, WHO). In fact, on several occasions guidelines issued by these 
organisations have been adopted (in part or in full) by the Community. 
One can mention the participation and co-sponsorship of the FIRST 
INTERNATIONAL CONFERENCE OF HARMONISATION (ICH), in 
which various possible areas for international (E.C., USA and Japan) 
cooperation in this field were identified and discussed. 
Thus it can be concluded that 1993 will mark the formation of one big 
European Market in 'which: 
1) Pharmaceuticals can move freely 
2) Cooperation between nations is promoted 
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3) The E.C. has one big say in cooperation initiatives on a world-
wide level (e.g. participation in the GATT [Uruguay] talks). 
Looking at Malta one immediately realises the need for the setting up of 
a Drug Regulatory Authority and a Testing and Certification Body. 
Further studies in this respect are needed. Help from WHO &/ or the 
E.C. can be asked for in this respect. 
Conclusion 
The completion of a European single market will benefit Pharmacy such 
that there is a greater exchange of ideas, knowledge, and experiences 
between the different national pharmaceutical societies. 
Pharmaceuticals will have facilitated mobility within Europe and 
possibly world-wide (through cooperation with other international 
organisations such as EFTA, NLN, USA, Japan). 
Unless MALTA starts now to enact legislative and administrative 
changes needed to bring its pharmaceutical sector in closer cohesion with 
that of Europe it will be left lagging behind. This will go against our 
obligations to protect and safeguard national health and safety 
standards and the need to improve them. 
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